AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$CRNX

Schilke Tobin sold (to issuer) $6.8M of CRNX

Schilke Tobin (Chief Financial & Infra. Ofcr.) sold (to issuer) 79,427 shares of Crinetics Pharmaceuticals, Inc. (CRNX) at $85.00 ($6.75M total) across 2 trades on 2026-09-01.

Original reporting
SEC EDGAR · Schilke Tobin
Published Sep 1, 2026, 8:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CRNX
Bearish
medium confidence
Mentioned
$CRNX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRNXBearishMed
01

Why it matters

The CFO's complete exit could be interpreted as a negative signal, prompting short sellers.

02

Market read

Primary source insider sale; modest materiality but actionable for short-term traders.

03

What to watch

The sale was at $85 per share, possibly above recent market price, indicating a fair valuation.

Relevance 6/10Novelty 7/10Timing: same day

Background

Form 4 filing discloses insider transactions; provides transparent insight into insider activity.

Company-level read

Ticker impact

$CRNXBearishMedium confidence
Context

Chief Financial & Infra. Officer sold all 79,427 shares for $6.75M, leaving zero holdings.

Expected impact

Short-term downward pressure expected.

Evidence & confidence

Sale represents a sizable insider stake liquidation; market may interpret as negative signal.

Market effects

Sector

May raise concerns for other small-cap biotech firms with insider sales.

Regional

Limited to US biotech sector.

Global

Low global impact.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • Company
    Crinetics Pharmaceuticals, Inc.

    Biotech firm listed on Nasdaq (CRNX).

  • Insider
    Schilke Tobin

    Chief Financial & Infra. Officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CRNX insider trading history →

Related articles

SEP 2
$VRTXHighAI 9/10

Vertex Completes $10 Billion Acquisition Of Crinetics Pharmaceuticals

Vertex Pharmaceuticals completed its $10 billion acquisition of Crinetics Pharmaceuticals, adding PALSONIFY and atumelnant to its portfolio. The deal, closed on September 1, 2026, is expected to boost revenue growth and become accretive to non-GAAP operating income by 2029. Vertex also announced leadership changes, including a new CFO.

pulse2.com2 min
SEP 2
$VRTXLowAI 9/10

What Does Crinetics Pharmaceuticals (CRNX) Delisting Mean After The Takeover Closed?

Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals (CRNX), delisting it from Nasdaq. Crinetics is now a subsidiary, with leadership changes announced. The $10B deal was funded by cash, debt, and $4.5B in bridge financing. Vertex gains exposure to Crinetics' endocrine disease treatments. Investors should watch for updates on pipeline and commercial priorities.

simplywall.st2 min
SEP 1
$VRTXHighAI 9/10

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Vertex Pharmaceuticals (VRTX) completed its $10B acquisition of Crinetics Pharmaceuticals (CRNX) on September 1, 2026. The deal adds PALSONIFY and atumelnant to Vertex's pipeline, with potential peak revenue of $5B. Vertex also announced leadership changes, including Jonathan Poole's appointment as EVP, CFO in 2027 and Jasper van Grunsven joining as EVP, Chief Pain and New Product Planning Officer.

investingnews.com2 min
AUG 30
$VRTXHighAI 9/10

Crinetics Acquisition Creates A ‘Fifth Commercial Pillar’ For Vertex, Says Analyst – Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock

Vertex Pharmaceuticals (VRTX) announced a $10 billion acquisition of Crinetics Pharmaceuticals (CRNX) for $85 per share, a 100% premium. Analyst Andrew Fein of H.C. Wainwright called it a strategic fit, adding a fifth commercial pillar. VRTX stock fell 2.5%, while CRNX surged 99%. Fein set a $641 price target for VRTX, a 24% upside. The deal is expected to close in Q3 2026 and contribute $5 billion in annual revenue by 2029.

stocktwits.com2 min